To the Editor:
Given the scarcity of rigorously designed trials in patients with congenital heart disease, Hsu et al must be commended for providing new insights into the effect of angiotensin-converting enzyme (ACE) inhibitors in infants with single ventricles. 1 Increased somatic growth has been reported in children with valvular regurgitation who have been treated with ACE inhibitors. 2 Whether this benefit translates to those born with univentricular physiology is an important question, given the burden of heart failure in this population.
The absence of effective medical treatments in this cohort reinforces the challenge of treating diastolic dysfunction, an early consequence of preload reduction in surgically palliated singleventricle patients. 3 Large-scale randomized, controlled trials have highlighted the limited efficacy of ACE inhibitors in reversing diastolic dysfunction and improving outcomes in adults with diastolic heart failure. Diastolic parameters have not yet been reported by Hsu et al. However, it seems unlikely that any change in diastolic function could be reliably assessed in this relatively small cohort of patients who have been treated for Ͻ14 months.
The ability of enalapril to regress ventricular hypertrophy and to improve systolic function makes assessment of ventricular size, mass, and function, important study endpoints. Echocardiography has been widely used in adult heart failure trials and provides a reliable assessment of changes in cardiac size and function. In contrast to adults with acquired heart disease, single-ventricle patients are anatomically diverse, making direct comparison difficult. Questions also remain about the accuracy of echocardiographyderived measurements in this population, where assumptions of uniform ventricular geometry do not apply. These limitations may be overcome by cardiac magnetic resonance imaging, the preferred modality for assessing ventricular mass in patients with complex cardiac morphology.
In evaluating the impact of ACE inhibitors in infants with single ventricles, Hsu et al have confirmed important differences in the pathophysiology of heart failure in congenital versus acquired heart disease. Their findings do not support the use of enalapril in infants with single-ventricle physiology. However, we would urge caution in translating this finding to single-ventricle patients as a population. Consistent with prior reports of maintained systolic function during the acute transition to the Fontan circulation, 4 most patients had preserved ventricular function in the absence of neurohormonal activation. The small subset of patients with systolic dysfunction, the high rate of drug discontinuation, and the inability to achieve target doses in many patients makes it difficult to draw any meaningful conclusions about the effect of enalapril on systolic dysfunction in this population.
As such, the question of whether ACE inhibitors can improve systolic dysfunction in single-ventricle patients remains unanswered. Systolic heart failure is a late manifestation in patients who have completed their Fontan surgery, associated with high morbidity, mortality, and few effective medical treatment options. 5 Given the high mortality associated with heart transplantation in patients with a Fontan circulation, we share the Pediatric Heart Network's enthusiasm for identifying effective medical treatments in this growing population.
